Literature DB >> 212190

Investigation of hormone-receptor interactions by means of fluorescence labeling.

W B Dandliker, R J Brawn, M L Hsu, P N Brawn, J Levin, C Y Meyers, V M Kolb.   

Abstract

Fluorescent-labeled hormones can be used to study hormone-receptor interactions by means of fluorescence polarization, visualization by fluorescence microscopy, or separation methods, e.g., dextran-coated charcoal. Subcellular fragments, single cells, and tissue preparations are amenable to study; in this work rat uterine cytosol was used unless otherwise noted. Estrone labeled with fluorescein at position 17 gives 50% inhibition in the radiometric dextran-coated charcoal assay at 8.3 X 10(-7) M as compared to 3.4 and 3.5 X 10(-8) M for diethylstilbestrol and estradiol, respectively. Scatchard plots from fluorescence polarization are hyperbolic and consistent with two classes of binding sites having association constants 5.6 X 10(10) and 6.4 X 10(7) M-1. Binding by high-affinity sites, which were present at about 3 times the concentraion of "specific" sites (radiometric dextran-coated charcoal assay), was abrogated by estradiol or diethylstilbestrol. Kinetic measurements showed that binding sites that can be blocked by excess estradiol or diethylstilbestrol are those that are both slowly associating and slowly dissociating. Staining of tissues by estrone labeled with fluorescein at position 17 as seen in the fluorescence microscope showed specificity. In normal rat uterus only epithelial cells were stained. In one human infiltrating ductal carcinoma only the malignant ductoid elements stained, while in another there was essentially no staining.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 212190

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Cytochemistry of sex steroid receptors: a critique.

Authors:  K S McCarty; D S Reintgen; H F Seigler; K S McCarty
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

2.  Estrogen receptors in gastric adenocarcinoma: a retrospective immunohistochemical analysis.

Authors:  H Yokozaki; N Takekura; A Takanashi; J Tabuchi; R Haruta; E Tahara
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

3.  The histochemistry of estrogen receptors.

Authors:  S H Lee
Journal:  Histochemistry       Date:  1981

4.  Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: comparison with that in frozen sections.

Authors:  A Shimada; S Kimura; K Abe; K Nagasaki; I Adachi; K Yamaguchi; M Suzuki; T Nakajima; L S Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

5.  Oestradiol-BSA conjugates for receptor histochemistry: problems of stability and interactions with cytosol.

Authors:  M Binder
Journal:  Histochem J       Date:  1984-09

6.  Ultrastructural evidence for endogenous testosterone immunoreactivity in the pituitary gland of the rat.

Authors:  G Morel; M G Forest; P M Dubois
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

7.  Immunohistologic and histochemical methods for detection of steroid binding in breast cancer: a reappraisal.

Authors:  L P Pertschuk; E H Tobin; A C Carter; K B Eisenberg; V C Leo; E Gaetjens; N D Bloom
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

8.  Synthesis and pharmacological characterization of fluorescent opioid receptor probes.

Authors:  V M Kolb; A D Koman; A Neil
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

9.  Sex steroid binding to human lymphocytes plasma membrane.

Authors:  N Tubiana; M Derre; Y Carcassonne; P M Martin
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

10.  Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors.

Authors:  K A Jacobson; K L Kirk; W L Padgett; J W Daly
Journal:  J Med Chem       Date:  1985-09       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.